Aclaris Therapeutics, Inc. ACRS
$3.70
-13.35%
at last close
Analyst Consensus
- Consensus Rating
- Buy (7 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $11.71
- Implied Upside
- +216.6%
- Price Target Range
- $10.00 – $16.00
- Analysts (12 mo)
- 7
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-09-01 | Canaccord GenuityEdward Nash |
Initiates coverage on | Buy | $10 |
| 2026-06-02 | LifeSci Capital |
Initiates coverage on | Outperform | $13 |
| 2026-05-05 | Piper SandlerBiren Amin |
Maintains | Overweight | $7 → $11 |
| 2026-05-05 | GuggenheimSeamus Fernandez |
Initiates coverage on | Buy | $12 |
| 2026-04-29 | WedbushMartin Fan |
Maintains | Outperform | $8 → $10 |
| 2026-04-16 | OppenheimerJeff Jones |
Initiates coverage on | Outperform | $10 |
| 2026-03-31 | WedbushMartin Fan |
Reiterates | Outperform | $8 |
| 2026-03-19 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $16 |
| 2026-01-28 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $16 |
| 2026-01-21 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $16 |
| 2025-10-20 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $16 |
| 2025-07-10 | Piper SandlerBiren Amin |
Assumes | Overweight | $6 |
| 2025-06-25 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $16 |
| 2025-05-28 | WedbushMartin Fan |
Initiates coverage on | Outperform | $8 |
| 2025-05-14 | HC Wainwright & Co.Raghuram Selvaraju |
Maintains | Buy | $20 → $16 |
| 2025-05-09 | ScotiabankLouise Chen |
Maintains | Sector outperform | $15 → $9 |
| 2025-03-18 | Cantor FitzgeraldPrakhar Agrawal |
Reiterates | Overweight | — |
| 2025-03-07 | ScotiabankLouise Chen |
Initiates coverage on | Sector outperform | $15 |
| 2024-12-23 | HC Wainwright & Co.Raghuram Selvaraju |
Upgrades | Neutral → Buy | $20 |
| 2024-11-19 | Leerink PartnersThomas Smith |
Upgrades | Market perform → Outperform | $2 → $7 |
| 2024-11-19 | JefferiesRoger Song |
Upgrades | Hold → Buy | $2 → $7 |
| 2024-11-19 | BTIGJulian Harrison |
Upgrades | Neutral → Buy | $8 |
| 2024-11-18 | Piper SandlerChristopher Raymond |
Upgrades | Neutral → Overweight | $3 → $13 |
| 2024-09-17 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Neutral | — |
| 2024-08-19 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Neutral | — |
| 2024-07-22 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Neutral | — |
| 2024-01-22 | HC Wainwright & Co.Raghuram Selvaraju |
Downgrades | Buy → Neutral | — |
| 2024-01-11 | BTIGJulian Harrison |
Downgrades | Buy → Neutral | — |
| 2023-12-29 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $9 |
| 2023-12-18 | StifelAlex Thompson |
Maintains | Hold | $2 → $1 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $3.70
- Market Cap
- $628.54 million
- 52-Week Range
- $1.74 – $6.60
- Average Volume
- 2.94 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.